This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency, to SRI International, a non-profit research and development institute. The $26,166.42 contract is for the analysis of anti-cancer chemicals and pharmaceutical formulations, including tests for appearance, NMR, IR, HPLC, residual solvents, moisture, residue on ignition, and heavy metals for a specific chemical compound, NSC 706744. This contract is part of a larger $26.2 million...
This federal contract award is for the production of 0.25mg of Azatdc and Tdcyd capsules, awarded to Societal Cdmo San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The contract, valued at $66,182.00, was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute. It is a delivery order under the Drug Formulation and Manufacturing Contracts 2019 Indefinite Delivery, Indefinite Quantity...
This is a federal contract award to Aapharmasyn LLC, a small disadvantaged business, for Experimental Therapeutics Medicinal Chemistry services. The contract was awarded by the Defense Health Agency, a component of the U.S. Department of Defense, with a ceiling value of $77,780.00. The contract has a firm fixed price pricing type and was awarded as a delivery order under the Experimental Therapeutics Medicinal Chemistry contract vehicle. The contract does not have a set-aside designation. The...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
This is a federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a leading contract research organization specializing in predictive toxicology and ADME (absorption, distribution, metabolism, and excretion) research. The $18,024.00 firm fixed-price purchase order contract is for the testing of two compounds against key ADME and DMPK (drug metabolism and...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $827,789 firm fixed price delivery order against its CRO Support for NCATS Drug Substance Development and Manufacture master IDIQ contract to Bachem Americas, Inc. to support the manufacture of 1 kg of CGMP L-ENK in support of the Center's drug substance development and manufacture program. Performance will take place in Torrance, California over a four-year...
This is a new task order awarded by the Food and Drug Administration (FDA) to Biopharma Services USA, Inc. under an existing contract (HHSF223201610004I) to perform a study titled "Evaluation of Formulation Dependence of Drug Interaction with Proton Pump Inhibitors (PPIs)." The task order is for an in vivo study of generic drug products in human subjects and has a not-to-exceed ceiling value of $1,320,689.00. The contract is a firm fixed price Delivery Order with a period of...
This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $157,158 contract is for the characterization of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of small-molecule drug candidates using standardized in vitro methods. This work supports...
The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $39,060 firm fixed price purchase order to Pharmaron, Inc. to evaluate absorption, distribution, metabolism, and excretion of compounds from an NIH dystonia research project. Per the sole source solicitation, Pharmaron will leverage its unique experience with the class of compounds to provide consistency and reproducibility in the evaluation process, compare new analogs to previous ones in the same...